AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Compugen Presents Pooled Analysis of COM701 in Platinum Resistant Ovarian Cancer at ESMO 2025
ByAinvest
Tuesday, Oct 14, 2025 1:00 am ET1min read
Compugen Ltd. will present a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at ESMO 2025. The analysis includes data from 60 evaluable patients and characterizes clinical benefit, progression-free survival, and safety profile. The presentation will include an additional year of follow-up data. Interim analysis results are expected at year-end 2026.
Compugen Ltd. will present a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at the European Society of Medical Oncology (ESMO) 2025 conference. The analysis, which includes data from 60 evaluable patients, characterizes clinical benefit, progression-free survival, and the safety profile of COM701. The presentation will also include an additional year of follow-up data. Interim analysis results are expected at year-end 2026 [1].The pooled analysis supports the rationale for evaluating COM701 as maintenance therapy in earlier lines of treatment. The data suggests that COM701 is well-tolerated and shows consistent, durable responses, particularly in patients without liver metastases. These results provide a basis for further clinical evaluation of COM701 in earlier settings of platinum-sensitive ovarian cancer [1].
Compugen is currently conducting the MAIA-ovarian trial, which assesses COM701 monotherapy as maintenance treatment in relapsed platinum-sensitive ovarian cancer. The company expects to conduct an interim analysis of the MAIA-ovarian trial once data from approximately 60 participants are available. Sites have been activated in the U.S., Israel, and France, with enrollment rates supporting an anticipated interim analysis by year-end 2026 [1].
Compugen's President and CEO, Eran Ophir, highlighted the potential of COM701 to change the disease trajectory and improve progression-free survival for patients with platinum-sensitive ovarian cancer who are ineligible for or cannot tolerate additional maintenance treatment. The company's financial outlook supports its operating plans well into 2027, with cash reserves expected to sustain these plans [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet